Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9579154 | PMC |
| http://dx.doi.org/10.1038/s41419-022-05332-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
m6A-modified lncRNA GAS5 promotes M1-polarization of microglia in alcohol use disorder.
Brain Res Bull
January 2025
Mental Health Center, the First Affiliated Hospital of Harbin Medical University, Heilongjiang, China. Electronic address:
Long noncoding RNA (lncRNA) are essential for modulating the onset and progression of alcohol use disorder (AUD). In this study, we investigated the molecular pathways through which lncRNA may contribute to AUD development. We assessed the expression levels of long noncoding RNA GAS5 (lncRNA GAS5) and microRNA-136-5p (miR-136-5p) in AUD tissue samples and cell lines using reverse transcription-quantitative polymerase chain reaction.
View Article and Find Full Text PDFFine-Scale Haplotype Mapping Reveals an Association of the Gene with Osteoporosis and Fracture Risk in Postmenopausal Women.
Genes (Basel)
September 2024
Department of Endocrinology, C. I. Parhon Institute of Endocrinology, Carol Davila University of Medicine and Pharmacy, 011863 Bucharest, Romania.
Introduction: The Fat Mass and Obesity-Associated () gene encodes a demethylase, which modulates RNA N6-methyladenosine (m6A) and plays a regulatory role in adipocyte differentiation and the pathogenesis of human obesity.
Methods: To understand the potential role of in osteoporosis (OP), we investigated five single nucleotide variations (SNVs) in intron 1 (rs8057044, rs8050136, rs9939609, rs62033406, and rs9930506) of the gene, and a missense SNV i.e.
Corrigendum to "N6-methyladenosine modified LINC00901 promotes pancreatic cancer progression through IGF2BP2/MYC axis" [Genes & Diseases 10 (2023) 554-567].
Genes Dis
November 2024
Cancer Center and Research Institute, University of Mississippi Medical Center, Jackson, MS 39216, USA.
[This corrects the article DOI: 10.1016/j.gendis.
View Article and Find Full Text PDFPublisher Correction: N6-methyladenosine-modified ALDH9A1 modulates lipid accumulation and tumor progression in clear cell renal cell carcinoma through the NPM1/IQGAP2/AKT signaling pathway.
Cell Death Dis
August 2024
Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Role of N‑methyladenosine in the pathogenesis, diagnosis and treatment of prostate cancer (Review).
Oncol Rep
June 2024
Department of Clinical Pharmacology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People's Hospital, Cancer Center, Westlake University School of Medicine, Hangzhou, Zhejiang 310006, P.R. China.
Prostate cancer (PCa) affects males of all racial and ethnic groups, and leads to higher rates of mortality in those belonging to a lower socioeconomic status due to the late detection of the disease. PCa affects middle‑aged males between the ages of 45 and 60 years, and is the highest cause of cancer‑associated mortality in Western countries. As the most abundant and common mRNA modification in higher eukaryotes, N‑methyladenosine (mA) is widely distributed in mammalian cells and influences various aspects of mRNA metabolism.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!